Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Aurinia Pharmaceuticals's Enterprise Value is $1,760.5 Mil.
Aurinia Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $175.2 Mil. Therefore, Aurinia Pharmaceuticals's EV-to-OCF for today is 10.05.
The historical rank and industry rank for Aurinia Pharmaceuticals's EV-to-OCF or its related term are showing as below:
AUPH'
s EV-to-OCF Range Over the Past 10 Years
Min: -467.81 Med: -8.44 Max: 38.62
Current: 10.05
During the past 13 years, the highest EV-to-OCF of Aurinia Pharmaceuticals was 38.62. The lowest was -467.81. And the median was -8.44.
AUPH's EV-to-OCF is ranked worse than 83.38% of 1408
companies
in the Biotechnology industry
Industry Median: -3.68
vs AUPH: 10.05
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aurinia Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Aurinia Pharmaceuticals's share price for today is $16.08.
Aurinia Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.290.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aurinia Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurinia Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's EV-to-OCF falls into.
Aurinia Pharmaceuticals's current Enterprise Value is $1,760.5 Mil.
Aurinia Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $175.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals (AUPH) has a EV-to-OCF of 10.05 as of Sep. 04, 2026. According to the industry distribution chart, Aurinia Pharmaceuticals ranks #1174 out of 1408 companies in the Biotechnology industry, placing it in the top 83.4%.
Is Aurinia Pharmaceuticals' EV-to-OCF too high?
Aurinia Pharmaceuticals' current EV-to-OCF is 10.05. Based on the distribution chart, Aurinia Pharmaceuticals ranks #1174 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aurinia Pharmaceuticals has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' EV-to-OCF compare to PVLA and SRPT?
According to the Biotechnology industry distribution chart, Aurinia Pharmaceuticals ranks #1174 out of 1408 companies for EV-to-OCF. This places Aurinia Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Aurinia Pharmaceuticals's current EV-to-OCF is 10.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Fairly Valued. The stock's GF Value™ is $14.76, compared to a current price of $16.08 — trading 8.9% above its estimated fair value. The current EV-to-OCF is 10.05. Aurinia Pharmaceuticals' overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current EV-to-OCF is 10.05 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued.
The current stock price of $16.08 is trading 8.9% above its estimated GF Value™ of $14.76.
GuruFocus considers Aurinia Pharmaceuticals to be Fairly Valued.
Key valuation signals for AUPH:
EV-to-OCF: 10.05
GF Value™: $14.76 vs. price of $16.08 (8.9% above fair value)
No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
81GF Score
Get the complete analysis for AUPH
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AUPH has been successfully added to your 
